United Medical Research Institute | Inglewood, CA

Research site

(Unclaimed)

Location

431-433 North Prairie Avenue, Inglewood, California, United States of America

Site insights

Top conditions

Top treatments

Latanoprost

VRDN-003

AR-13324

AR-12286

AGN-190584

KPI-121

Netarsudil

ISV-502

VVN461

Lifitegrast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 32 total trials

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants with Thyroid Eye Disease (TED) (STRIVE)

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-...

Active, not recruiting

Thyroid Eye Disease

Drug: VRDN-001 10 mg/kg

Drug: VRDN-001 3 mg/kg

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).

Enrolling

Thyroid Eye Disease (TED)

Drug: VRDN-003

Drug: Placebo

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the...

Enrolling

Open-angle Glaucoma

Ocular Hypertension

Other: Sham Administration

Drug: AGN-193408 SR

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) (REVEAL-1)

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid E...

Enrolling

Thyroid Eye Disease

Drug: VRDN-003

Drug: Placebo

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED) (REVEAL-2)

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid...

Enrolling

Thyroid Eye Disease

Drug: Placebo

Drug: VRDN-003

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalm...

Active, not recruiting

Glaucoma

Ocular Hypertension

Drug: Rhopressa®

Drug: T4090 0.3%

Next Generation Rocklatan

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects...

Enrolling

Open Angle Glaucoma

Ocular Hypertension

Drug: AR-17043 Ophthalmic Solution

Drug: Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution